All 17 patients in one group saw tumors shrink or stay stable in Perspective Therapeutics' trial.

Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Other Events. Perspective Therapeutics Presents Promising [212Pb]Lapemelanotide Zapixetar (VMT01) Monotherapy Data from a Phase 1/2a Study in Heavily Pretreated Advanced Melanoma Patients at SITC 2026 • Meaningful antitumor activity observed at the 3.0 mCi monotherapy dose with 75% disease con

Perspective Therapeutics (CATX) reported interim Phase 1/2a data for VMT01, showing 2 partial responses in 8 patients at the 3.0 mCi dose, with a 75% disease control rate. No dose-limiting toxicities or treatment-related serious adverse events were reported across 20 patients. The company continues dose optimization for future development.

Perspective Therapeutics (CATX) reported interim Phase 1/2a trial results for its melanoma treatment, lapemelanotide. Two of eight patients at the 3.0 mCi dose showed tumor shrinkage, with one response lasting ~40 weeks. No serious adverse events were reported. The company plans to continue dose optimization and development.

Perspective Therapeutics reported positive Phase 1/2a trial data for bamzireotide, showing 75% 18-month progression-free survival in GEP-NET patients. The company targets an end-of-Phase 2 meeting in 1Q 2027. No serious adverse events were reported.

Perspective Therapeutics, Inc. (CATX) filed an SEC Form 8-K — Other Events. Perspective Therapeutics Presents Encouraging Incremental Data and Analyses from Phase 1/2a Trial of [212Pb]Bamzireotide Navoxetan (VMT-α-NET) in Advanced SSTR2 Expressing NETs • Additional analyses presented at NANETS 2026 Multidisciplinary NET Medical Symposium support prior fi

Perspective Therapeutics (CATX) reported 75% progression-free survival at 18 months in 57 GEP-NET patients expressing SSTR2 in a retrospective analysis. The company aims for an end-of-Phase 2 meeting in Q1 2027 and a Phase 3 start in 2027, pending FDA feedback and completion of required activities.